IMBRUVICA Ibrutinib 140mg

Imbruvica (Ibrutinib) is a prescription drug used to treat Mantle-cell lymphoma, Blood cancer (Chronic lymphocytic leukemia).

Manufacturer : Janssen Pharmaceuticals

Strengths available :  140mg

Storage : Store at temperature below 30°C

Dosage :

• Administer IMBRUVICA orally once daily at approximately the same time each day.
• Swallow the capsules whole with water.
• Do not open, break, or chew the capsules.

Mantle Cell Lymphoma and Marginal Zone Lymphoma

​The recommended dose of IMBRUVICA for MCL and MZL is 560 mg (four 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström’s Macroglobulinemia

The recommended dose of IMBRUVICA for CLL/SLL and WM is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

The recommended dose of IMBRUVICA for CLL/SLL when used in combination with bendamustine and rituximab (administered every 28 days for up to 6 cycles) is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

​Chronic Graft versus Host Disease

​The recommended dose of IMBRUVICA for cGVHD is 420 mg (three 140 mg capsules) orally once daily until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity. When a patient no longer requires therapy for the treatment of cGVHD, IMBRU

Most common side effects are Headache, Joint pain, Fever, Diarrhoea, Vomiting, Stomatitis (Inflammation of the mouth), Nausea, Constipation, Reduced blood platelets, Decreased white blood cell count (neutrophils), Upper respiratory tract infection.

Pack of 90 and 120 capsules